ESTRO 2025 - Abstract Book

S2076

Clinical - Urology

ESTRO 2025

months (3.5 – 42.4). Table1 displays their baseline demographic and clinical characteristics. Acute and late toxicity were evaluable in 98 and 94 patients, respectively. Acute GU toxicity rates (number) were G0 79.5% (78), G1 20.4% (20), and G2 0% (0), while rates of late GU side effects were G0 65.9% (62), G1 26.6% (25), G2 6.4% (6), and G3 1.1% (1). Acute GI toxicity rates were G0 89.7% (88), G1 5.1% (5), and G2 5.1% (5), while rates of late GI side effects were G0 92.6% (87), G1 6.4% (6), and G2 1.1% (1). Among PROs, most domains showed no significant changes from baseline to late follow-up, except for EPIC Urinary Incontinence, which trended toward significance (P=0.0587, Table2 ). The MID analysis revealed that late QoL deteriorated in 26 patients, with sexual function and urinary incontinence being the most affected domains (13 and 23 patients, respectively, Table 3). Eighteen patients experienced biochemical recurrence (median 10 months; range, 3.5 – 41.5), resulting in BRFS rates of 96.3%, 90.0%, 85.3%, and 79.2% at 6, 12, 18 and 24 months, respectively ( Figure1 ). Cox-regression identified ISUP grade as a significant predictor of recurrence risk (HR=1.58, P=0.036; BRFS at 12 months: 100% vs. 94.1% vs. 86.8% vs. 90.9% vs. 75% for ISUP grades from 1 to 5, respectively, Figure2 ). Two recurrences were found within the radiation field.